Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: A national survey

Chest

Volumn 128, Issue 4, 2005, Pages 2765-2771

  Prais, Dario ^a,c   Danino, Dana ^b   Schonfeld, Tommy ^a   Amir, Jacob ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Bronchiolitis; Palivizumab; Pediatric ICU; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ADOLESCENT; ARTIFICIAL VENTILATION; BRONCHIOLITIS; CHILD; CHILDHOOD MORTALITY; CHRONIC LUNG DISEASE; DISEASE SEVERITY; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; ISRAEL; MAJOR CLINICAL STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT OUTCOME; VIRAL BRONCHIOLITIS; VIRUS INFECTION;

EID: 27144511649     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2765     Document Type: Article

References (25)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917-1928
2. McIntosh EDG. Respiratory syncytial virus infections in infants and children: diagnosis and treatment. Pediatr Rev 1987; 9:191-196
3. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203
4. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants less than 32 weeks' gestation. Pediatrics 1991; 88:527-532
5. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic-administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-1530
6. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalisation among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:93-99
7. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537
8. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102:1211-1216
9. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1442-1446
10. The Israel Ministry of Health, Medical Administration. RSV prophylaxis. Available at: http://www.health.gov.il. Accessed September 28, 2005
11. Prais D, Schonfeld T, Amir J. Admissions to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 2003; 112:548-552
12. Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003; 22:483-489
13. Swenson PD, Kaplan MH. Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by a commercial enzyme immunoassay. J Clin Microbiol 1986; 23:485-488
14. Israel Disease Control Center. Very low birth weight children in Israel: annual National Report. Tel Aviv, Israel: Israel Neonatal Network, September 2002
15. Kamal-Bahl S, Doshi J, Campbell J. Economic analysis of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002; 156:1034-1041
16. Lofland UH, O'Connoe JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000; 22:1357-1369
17. Marchetti A, Lau H, Magar R, Wang L, et al. Impact of palivizumab on expected cost of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999; 21:752-766
18. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or early. Arch Pediatr Adolesc Med 2000; 154:55-61
19. Clark SJ, Beresford MW, Subjedar NV, et al. Respiratory syncytial virus infection in high-risk infants and the potential of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000; 83:313-316
20. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decision and costs. Pediatr Pulmonol 2001; 32:20-28
21. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med 2002; 156:1251-1255
22. Numa A. Outcome of respiratory syncytial virus infection and cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000; 36:422-427
23. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104:419-427
24. Roeckl-Wiedmann T, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162:237-244
25. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-540